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Immunity
Previewswas a hematopoietic cell. When infected,
are all parenchymal cells equally endowed
with the ability to lure CD8+ T cells?
Target-mediated chemoattraction is also
likely to vary among different infections.
Indeed, viruses, including vaccinia, are
known to employ strategies that interfere
with chemotaxis. It will be important to
further determine the range of cues that
trigger and regulate this process within
thehost, thepotential involvement of other
chemokines, and the various strategies
that professional pathogens might utilize
to evade it. Nevertheless, by showing
that infected cells call their killers to the
scene of the crime, Hickman et al. high-
light a fundamental aspect of immunosur-
veillance in peripheral tissues.REFERENCES
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Cigarette smoke and infection are the major drivers of chronic obstructive pulmonary disease. In this issue of
Immunity, Kearley et al. (2015) demonstrate that smoke exposure alters the lung microenvironment leading
to an interleukin-33-dependent proinflammatory disease exacerbation.Chronic obstructive pulmonary disease
(COPD) is a chronic lung disorder with
irreversible and progressive airflow
obstruction associated with prolonged
and enhanced inflammatory response.
COPD is a major cause of morbidity and
mortality worldwide. Cigarette smoke
exposure is considered the primary
causative agent of COPD. The disease is
exacerbated by viral infections such as
rhinovirus or influenza virus or bacterial
infection. There is no effective treatment
for COPD. Inflammatory cytokines, inter-
feron-a (IFN-a), IFN-g, TNF-a, inter-
leukin-12 (IL-12), IL-23, IL-1a, and IL-18
have been implicated to play a role
in human COPD and mouse models.
However, the mechanism by which
smoking and infection interact to aggra-
vate COPD remains poorly understood.In this issue of Immunity, Kearley et al.
(2015) show that cigarette smoke alters
the lung microenvironment to facilitate
an alternative IL-33-dependent exagger-
ated proinflammatory response to infec-
tion leading to exacerbated COPD.
IL-33 is a member of the IL-1 family
(Schmitz et al., 2005), has an important
role in the induction and modulation of
immune responses, and has been linked
to a variety of inflammatory diseases,
such as rheumatoid arthritis, asthma,
and cardiovascular diseases (Liew et al.,
2010). Intracellular IL-33 is constitutively
expressed in the nuclei of a variety of
cell types, including epithelia, endothelia,
and fibroblasts, where it functions as a
nuclear factor with regulatory properties.
Mature IL-33 is released from the cells
normally after cell damage or necrosis.Extracellular IL-33 acts via its cognate
receptor ST2 that exists in membrane-
bound form (mST2) and signals via the
canonical IL-1R signaling cascade that
leads to activation of NF-kB and MAPK
signaling with subsequent induction
of proinflammatory immune responses
and cytokine production. By alternative
splicing of ST2, ST2 is also expressed in
a soluble form (sST2) lacking intracellular
signaling and thus functions as a decoy
receptor neutralizing IL-33 activity. Thus,
the immune system has evolved to detect
and regulate extracellular IL-33, which is
believed to function as an ‘‘alarmin’’ to
signal cellular damage. A recent study
showed that IL-33 is substantially
elevated in severe COPD patients (Byers
et al., 2013) and is associated with an IL-
13 and mucin gene-like signature.2, March 17, 2015 ª2015 Elsevier Inc. 401
Figure 1. Cigarette Smoke Exacerbates COPD via Induction of IL-33, NK Cells, and IFN-g
Cigarette smoke induces lung epithelial cells to produce increased levels of intracellular IL-33, which is
released upon cell damage by viral or bacterial infection. Smoke exposure, via a yet undefined mecha-
nism, downregulates the expression of IL-33 receptor (ST2) on group 2 innate lymphoid cells (ILC2s)
but upregulates ST2 expression on macrophages (M0) and natural killer cells (NK). This leads to the
shutdown of ILC2 responses and type II cytokine synthesis normally induced by IL-33. In contrast,
IL-33 is now able to activate macrophages to produce IL-12, which synergizes with IL-33 to induce the
proliferation of NK cells and the heightened production of the proinflammatory cytokine IFN-g leading
to exacerbated COPD.
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PreviewsKearley et al. (2015) first exposed ST2-
or IL-33-deficient or BALB/c mice to ciga-
rette smoke and subsequently infected
them with influenza A virus. Prior smoke
exposure in BALB/c mice significantly
enhanced weight loss to infection and
exaggerated lung inflammation com-
pared to viral infection alone. However,
IL-33 or ST2 deficiency completely pro-
tected mice from these exacerbated
responses. Furthermore, administration
of sST2 also protected mice from exacer-
bated inflammation. These results thus
show that IL-33 is an essential trigger
of COPD exacerbation in mice. Kearley
et al. (2015) then showed that smoke
exposure markedly upregulated IL-33
expression in the lung alveolar type II
pneumocytes and in the bronchial epithe-
lium. However, there was no evidence
that IL-33 was released into the bronchial402 Immunity 42, March 17, 2015 ª2015 Elsealveolar lavage (BAL). IL-33 release was
induced by viral-mediated cellular dam-
age. Thus smoke is required to enhance
IL-33 expression in the epithelium and
viral infection led to IL-33 release into
the BAL. Consistent with this notion, local
administration of recombinant IL-33 after
virus infection recapitulated many of the
enhanced response seen after smoke
plus virus infection.
To dissect the mechanism involved,
Kearley et al. (2015) analyzed the cellular
components in the lungs altered by smoke
and virus infection. Because IL-33 is a
potent inducer of Th2 cells (Schmitz
et al., 2005) and type II innate lymphoid
cells (ILC2s) (Kim et al., 2012), it was
contra-intuitive that smoke exposure led
to a robust production of T helper 1
(Th1) cell-like proinflammatory cytokines
(TNF-a, IL-12, and IFN-g) and diminutionvier Inc.of ILC2 frequency and function (produc-
tion of IL-5 and IL-13) in the lungs. Further
analyses revealed that smoke and virus
infection expanded type I macrophage
and natural killer (NK) cell functions. Acti-
vated macrophages produce IL-12, which
induces NK cells to produce heightened
levels of IFN-g, leading to increased
cellular inflammation in the lungs.
Because ILC2s, macrophages, and
NK cells express varying amounts of
cell surface ST2, the next question was
whether smoke exposure led to a differ-
ential expression of ST2 on these cell
types. Surprisingly, continuous smoke
exposure induced a dramatic loss of ST2
mRNA and cell surface expression in
ILC2s but a significant increase of ST2
message in NK cells, macrophages, and
dendritic cells. Furthermore, IL-33 syner-
gized with IL-12 to induce robust IFN-g
production by NK cells. Thus, smoke
exposure impairs the ability of the lung
to mount a Th2 cell response by regu-
lating ST2 expression on ILC2s, while it
increases IFN-g production by elevating
ST2 expression on NK cells (Figure 1).
Kearley et al. (2015) went on to inves-
tigate the clinical relevance of their obser-
vation. Consistent with a previous report
(Byers et al., 2013), IL-33 was found to
be more abundant in the epithelium of
the lung of COPD patients compared
to non-COPD individuals. Furthermore,
IL-33 expression correlated well with dis-
ease severity, with the highest amounts
being observed in the most severe
COPD patients (GOLD IV, Global Initiative
for Chronic Obstructive Lung Disease,
stage IV).
Earlier studies have shown that ciga-
rette smoke and infection are typically
associatedwith COPD (Sethi andMurphy,
2008). Elevated IL-33 expression in the
lung epithelium of COPD patients has
also been reported (Byers et al., 2013).
More recently, cigarette smoke exposure
(with speculative environmental infection)
has been shown to induce COPD via
increased IL-33 expression in the lungs
of mice (Qiu et al., 2013). The study of
Kearley et al. (2015) links these obser-
vations together and provides cellular
and molecular insight into the interac-
tion of smoke exposure, infection, and
IL-33 in the manifestation of COPD. This
study also presents data in apparent
contrast to some of the prevailing para-
digms of IL-33.
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PreviewsSince the observation that ST2 is selec-
tively expressed on Th2 cells and not on
Th1 cells (Xu et al., 1998) and that IL-33
preferentially activates Th2 cells (Schmitz
et al., 2005), IL-33 has been closely asso-
ciated with type II immune response.
The report of Kearley et al. (2015) is in
apparent contrast to this paradigm.
Several recent studies also suggest that
IL-33 can activate NK cells (Bourgeois
et al., 2009) to produce the canonical
Th1-like cytokine IFN-g. There is so far
no report of a direct activation of Th1
cells. However, as suggested by Kearley
et al. (2015), IL-33 is probably a pleio-
tropic cytokine whose function extends
beyond the confine of type II response
when combined with other cytokines in
the alternated microenvironment (such
as caused by smoke and infection in the
lung), in the absence of which IL-33 would
induce a type II response by default.
Several earlier reports also show that
IL-33 preferentially induces alternatively
activated macrophage (M2) rather than
classically activated macrophage (M1)
(Kurowska-Stolarska et al., 2009). How-
ever, IL-33 appears to do so indirectly
via the induction of IL-4 and IL-13 pro-
duced by Th2 cells and ILC2s. Kearley
et al. (2015) show that in the absence
of type II cytokines, IL-33 can activate
M1 by upregulating the expression
of ST2 on macrophages. Thus, againthe action of IL-33 on macrophages
is highly dependent on the milieu of
microenvironment.
It should be noted that the pathogen-
esis of COPD is distinct from that of
asthma. COPD is mediated mainly by
the infiltration of inflammatory cells acti-
vated by type I cytokines, whereas
asthma is an allergic response principally
induced by type II cytokines. Thus,
whereas IL-33 can directly elicit an
asthmatic response, smoke-exposure-
induced IL-33, released from the epithe-
lium by concomitant infections, probably
activates a type I response via the differ-
ential modulation of ST2 expression on
ILC2s, macrophages, and NK cells.
The report of Kearley et al. (2015) raises
a number of intriguing questions. What
are the components in the cigarette
smoke that induce elevated expression
of IL-33 in the lung epithelium? What is
the mechanism by which these compo-
nents increase IL-33 expression? How
does smoke exposure differentially regu-
late ST2 expression on ILC2s, macro-
phages, and NK cells? Answers to these
questions would not only provide further
insight into the molecular pathway of
IL-33 function, but also pave the way for
a more effective treatment of the unmet
clinical needs of COPD. Targeting IL-33
by sST2 and anti-IL-33 antibody merits
investigation in clinical COPD.Immunity 4REFERENCES
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Central nervous system trauma induces marked inflammation that has beneficial and deleterious conse-
quences. In a recent issue of Neuron, Gadani et al. (2015) show that injured spinal cord releases the alarmin
IL-33 to drive chemokines that recruit monocytes and promote recovery.It has been long debated whether the
inflammation following central nervous
system (CNS) injury impairs or aids re-
covery. Inflammation is an essential pro-
tective response, killing pathogens andremoving necrotic material, but its
‘‘weapons’’ need to be carefully regulated
to prevent excessive tissue damage. This
is especially the case in the CNS, a tissue
with limited, if any, capacity to regenerate(Norenberg et al., 2004). Much of the
damage seen after injury might not
actually be due to the initial insult but
to secondary inflammation, character-
ized by ischemia, edema, and free-radical2, March 17, 2015 ª2015 Elsevier Inc. 403
